The role of valproate in metabolic disturbances in bipolar disorder patients
- PMID: 20060174
- DOI: 10.1016/j.jad.2009.12.011
The role of valproate in metabolic disturbances in bipolar disorder patients
Abstract
Background: Our previous report showed that patients with bipolar disorder (BD) have higher prevalence of hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL) and obesity in Taiwan. To confirm whether the metabolic disturbances is associated with the disease itself or the medications used for treating BD, we further compared the metabolic status among the valproate (VPA) treated BD patients, drug-free BD patients and healthy controls in Taiwan.
Method: This cross-sectional study included 119 healthy controls and 77 BD patients diagnosed according to the DSMIV-TR criteria in a university hospital. Among the diseased group, 25 remitted BD patients were drug-free (BD-F), and 52 of them were treated with VPA (BD-VPA). Their body mass index (BMI), plasma glucose levels and plasma lipid profiles were measured.
Results: Plasma fasting glucose, insulin, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL) levels were significantly different among BD-VPA, the BD-F, and the healthy control groups. Valproate treatment was associated with significant higher plasma insulin, triglyceride, and BMI levels as well as lower fasting glucose and HDL levels. However, these biochemical indexes did not differ significantly between the BD-F and the healthy control groups.
Conclusion: These results provide further evidence that VPA treatment for BD may increase the risk of metabolic disturbances. The risk may be reduced after discontinuing VPA medication.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan.J Affect Disord. 2009 Sep;117(1-2):124-9. doi: 10.1016/j.jad.2008.12.018. Epub 2009 Feb 4. J Affect Disord. 2009. PMID: 19193445
-
Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.Aust N Z J Psychiatry. 2009 Jan;43(1):53-60. doi: 10.1080/00048670802534341. Aust N Z J Psychiatry. 2009. PMID: 19085528
-
Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.Epilepsy Behav. 2006 May;8(3):643-8. doi: 10.1016/j.yebeh.2006.02.008. Epub 2006 Apr 5. Epilepsy Behav. 2006. PMID: 16600693
-
Metabolic and endocrine effects of valproic acid chronic treatment.Epilepsy Res. 2013 Nov;107(1-2):1-8. doi: 10.1016/j.eplepsyres.2013.08.016. Epub 2013 Sep 4. Epilepsy Res. 2013. PMID: 24076030 Review.
-
Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis.Eur J Obstet Gynecol Reprod Biol. 2016 Jul;202:26-31. doi: 10.1016/j.ejogrb.2016.04.038. Epub 2016 Apr 30. Eur J Obstet Gynecol Reprod Biol. 2016. PMID: 27160812 Review.
Cited by
-
Chronotolerance study of the antiepileptic drug valproic acid in mice.J Circadian Rhythms. 2012 May 10;10:3. doi: 10.1186/1740-3391-10-3. J Circadian Rhythms. 2012. PMID: 22574933 Free PMC article.
-
Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.J Psychiatr Pract. 2016 May;22(3):175-82. doi: 10.1097/PRA.0000000000000149. J Psychiatr Pract. 2016. PMID: 27123797 Free PMC article.
-
Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit.Ther Adv Psychopharmacol. 2022 Aug 23;12:20451253221110016. doi: 10.1177/20451253221110016. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 36051503 Free PMC article.
-
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.World Psychiatry. 2015 Jun;14(2):119-36. doi: 10.1002/wps.20204. World Psychiatry. 2015. PMID: 26043321 Free PMC article.
-
Comparison of Rates of Type 2 Diabetes in Adults and Children Treated With Anticonvulsant Mood Stabilizers.JAMA Netw Open. 2022 Apr 1;5(4):e226484. doi: 10.1001/jamanetworkopen.2022.6484. JAMA Netw Open. 2022. PMID: 35385086 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical